HI
NTLA icon

Hudock Inc’s Intellia Therapeutics NTLA Stock Holding History

Hudock Inc’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-25
Closed -$1K – 517
2022
Q3 		$1K Hold
25
– – ﹤0.01% 722
2022
Q2 		$1K Hold
25
– – ﹤0.01% 711
2022
Q1 		$1K Hold
25
– – ﹤0.01% 715
2021
Q4 		$2K Hold
25
– – ﹤0.01% 692
2021
Q3 		$3K Buy
+25
New +$3.79K ﹤0.01% 726

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Hudock Inc's NTLA Position: Q4 2022 in Review

Hudock Inc sold out of Intellia Therapeutics (NTLA) in Q4 2022, closing a stake of 25 shares — an estimated $1K sold.

Hudock Inc first reported a position in NTLA in Q3 2021 and held it in 5 quarters. The position peaked at $3K in Q3 2021. 303 funds tracked by Wall St. Rank hold NTLA as of Q4 2022.

  • Hudock Inc reported no remaining Intellia Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Hudock Inc sold 25 Intellia Therapeutics shares in Q4 2022, an estimated $1K.
  • Hudock Inc first reported a position in Intellia Therapeutics in Q3 2021 and held it in 5 quarters.
  • Hudock Inc's Intellia Therapeutics position peaked at $3K in Q3 2021.
  • 303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2022.

Based on Hudock Inc's 13F filing for Q4 2022, filed 8 Feb 2023.